Lexicon Wins Big with SOLOIST and SCORED

Late yesterday, results from the sotagliflozin CVOTs (SOLOIST-WHF and SCORED) were presented at the AHA 2020 conference (view press release) and simultaneously published in the NEJM (SOLOIST-WHF publication and SCORED publication). Somewhat surprisingly, both trials demonstrated highly statistically significant CV benefits despite the fact that they were closed early due to financial and strategic reasons (previous FENIX insight). Below, FENIX provides an overview of the SOLOIST and SCORED results as well as implications to the SGLT2i class and beyond.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.